Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Retained Earnings (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Retained Earnings for 3 consecutive years, with -$1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 194759.69% to -$1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 billion, a 194759.69% decrease, with the full-year FY2025 number at -$1.1 billion, down 194759.69% from a year prior.
  • Retained Earnings was -$1.1 billion for Q4 2025 at Nuvation Bio, down from -$139000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $1.4 million in Q3 2024 to a low of -$1.1 billion in Q4 2025.
  • A 3-year average of -$259.5 million and a median of -$2.1 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: soared 216.57% in 2024, then plummeted 194759.69% in 2025.
  • Nuvation Bio's Retained Earnings stood at $181000.0 in 2023, then skyrocketed by 216.57% to $573000.0 in 2024, then tumbled by 194759.69% to -$1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Retained Earnings are -$1.1 billion (Q4 2025), -$139000.0 (Q3 2025), and -$1.0 billion (Q2 2025).